Minimally Invasive Surgery and Laparotomy Yield Similar OS in Ovarian Cancer

Video
Conference|Society of Gynecologic Oncology Annual Meeting on Women’s Cancer (SGO)

Minimally invasive surgery for interval debulking resulted in a lower mortality at the 30- and 90-day time points compared with laparotomy in advanced ovarian cancer.

Data indicate that there is no notable difference in survival when using minimally invasive surgery for interval debulking vs laparotomy in patients with advanced ovarian cancer, according to Kirsten Jorgensen, MD.

In an interview with CancerNetwork® during The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, Jorgensen, a fellow at The University of Texas MD Anderson Cancer Center, also detailed that despite undergoing more extensive surgery, laparotomy did not provide an additional mortality benefit and that the minimally invasive group was discharged from the hospital faster with a shorter treatment interval.

Moreover, mortality was lower in the minimally invasive group vs the laparotomy group at the 30- and 90-day time points.

Transcript:

The major finding was that there was no worse overall survival for minimally invasive surgery when compared with laparotomy. This also included no worse overall survival at the 5-year estimated overall survival and the overall analysis.

Additionally, we did find that for the laparotomy group, there was more extensive surgery, but this didn’t come with any added mortality benefit. They [also] had higher rates of residual disease. Similar to prior studies, we also found that the minimally invasive group got out of the hospital faster and had shorter treatment time in the hospital.

We did find that there was lower mortality at the 30- and 90-day mark in the minimally invasive group. However, this was a rare outcome overall in both of our groups. Similarly, both groups had low rates of readmission. We were unable to measure complications from surgery directly due to the limitations of the dataset. We are hopeful that this is an avenue for future research, especially prospective research.

Reference

Jorgensen K, Wu FC, Nitecki R, et al. Laparotomy vs minimally invasive surgery for interval debulking surgery among patients with advanced ovarian cancer. Presented at: 2023 Annual Meeting on Women’s Cancer; March 25-28; Tampa, Florida.

Recent Videos
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
Related Content
Although both immune priming strategies numerically improved ORR and PFS vs olaparib monotherapy, the study was not powered for comparisons between arms.

Immune Priming Strategies Numerically Improve PFS in Ovarian Cancer

Roman Fabbricatore
November 24th 2025
Article

Although both immune priming strategies numerically improved ORR and PFS vs olaparib monotherapy, the study was not powered for comparisons between arms.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

According to Toru Kondo, PhD, EVA1-ADC is able to target glioblastoma-initiating cells while sparing normal cells and stem cells during treatment.

Will Targeting EVA1 With ADCs Eliminate Glioblastoma-Initiating Cells?

Tim Cortese
November 16th 2025
Article

According to Toru Kondo, PhD, EVA1-ADC is able to target glioblastoma-initiating cells while sparing normal cells and stem cells during treatment.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.

Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC

Russ Conroy
November 15th 2025
Article

Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.

Although the study was underpowered due to a small sample size, non-significant improvements in functional and social well-being occurred with MOST-S26.

Nurse-Led Telehealth Displays Feasibility in Ovarian Cancer Follow-Up

Roman Fabbricatore
November 14th 2025
Article

Although the study was underpowered due to a small sample size, nonsignificant improvements in functional and social well-being occurred with MOST-S26.